HPV-FASTER Explained
What is HPV FASTER?
HPV FASTER is a public health strategy proposing a combined approach to HPV vaccination and HPV screening for women aged 25–45 years.
The aim is to prevent cervical cancer more quickly by vaccinating and screening a wider age group in parallel.
Main Goal
To prevent cervical cancer faster by vaccinating and screening women who may have already been exposed to HPV but do not yet show disease.
How It Works Technically
Dual Intervention Strategy:
- HPV Vaccination: Administered to women up to 45 years, even if previously exposed. Nonavalent vaccines are used for broader coverage.
- HPV-Based Screening: Uses HPV DNA testing, which is more sensitive than Pap tests, to detect and treat existing infections or precancerous lesions.
Age Targeting (25–45 years): Focuses on a group often missed by adolescent vaccination programs and under-screened in many regions.
Benefits of the HPV FASTER Strategy
Faster reduction in cervical cancer incidence and mortality.
Higher cost-effectiveness through combined interventions.
Reduced long-term screening frequency.
Increased population immunity, even among partially exposed women.
HPV-Faster-Implement Project: Implementation Aspects
Research & Evidence Base: Built on clinical trials and modeling demonstrating benefits of adult vaccination plus screening.
Integration into Health Systems: Combines vaccine and screening delivery in primary care or gynecology, with digital registry support.
Equity Focus: Aimed at regions with low vaccine uptake and inconsistent screening, such as parts of Eastern Europe.
Global & EU Alignment
Supports WHO’s 90-70-90 targets and the EU Beating Cancer Plan.
Aligned with WHO’s cervical cancer elimination goals.